The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target

Molecular Pharmacology

Volumn 68, Issue 3, 2005, Pages 563-567

  Houslay, Miles D ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR;

ACETYLATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENETICS; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROKE; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS;

EID: 23944510412     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.015719     Document Type: Review

References (54)

1. Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER, and Conti M (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 48:616-622.
2. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, and Conti M (2004) Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173:7531-7538.
3. Baillie G, MacKenzie SJ, and Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60:1100-1111.
4. Baillie GS and Houslay MD (2005) Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17:129-134.
5. Baillie GS, MacKenzie SJ, McPhee I, and Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131:811-819.
6. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, and Houslay MD (2003) Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100:940-945.
7. Balmanno K, Millar T, McMahon M, and Cook SJ (2003) DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry. Mol Cell Biol 23:9303-9317.
8. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, and Heeke GV (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD and nonsmokers. Am J Physiol 287:L332-L343.
9. Bevan S, Porteous L, Sitzer M, and Markus HS (2005) Phosphodiesterase 4D gene, ischemic stroke and asymptomatic carotid atherosclerosis. Stroke 36:949-953.
10. Bos JL (2003) Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4:733-738.
11. Cao D, Wang Z, Zhang CL, Oh J, Xing W, Li S, Richardson JA, Wang DZ, and Olson EN (2005) Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. Mol Cell Biol 25:364-376.
12. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, et al. (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207.
13. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMP specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
14. Fleming YM, Frame MC, and Houslay MD (2004) PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci 117(Pt 11):2377-2388.
15. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, et al. (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35:131-138.
16. Gulcher JR, Gretarsdottir S, Helgadottir A, and Stefansson K (2005) Genes contributing to risk for common forms of stroke. Trends Mol Med 11:217-224.
17. Hansen G, Jin S, Umetsu DT, and Conti M (2000) Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97:6751-6756.
18. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, and Ogihara T (2000) Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 35:237-243.
19. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, and Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO (Eur Mol Biol Organ) J 18:893-903.
20. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18.
21. Houslay MD and Kolch W (2000) Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-668.
22. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, et al. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:1967-1976.
23. Jeffery P (2005) Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm Pharmacol Ther 18:9-17.
24. Jin SL and Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99:7628-7633.
25. Koyama H, Bornfeldt KE, Fukumoto S, and Nishizawa Y (2001) Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1-10.
26. Kronemann N, Nockher WA, Busse R, and Schini-Kerth VB (1999) Growthinhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: effect on cell cycle and cyclin expression. Br J Pharmacol 126:349-357.
27. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 277:35980-35989.
28. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-175.
29. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, and Maurice DH (2000) Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615-26624.
30. Lohmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, Meitinger T, and Dichgans M (2005) ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36:731-736.
31. 2-adrenergic receptor to activation of ERK in HEK293 cells. J Biol Chem, in press.
32. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, and Houslay MD (2000) ERK2 mitogen-activated protein kinase binding, phosphorylation and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275:16609-16617.
33. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, and Houslay MD (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 136:421-433.
34. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, and Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546.
35. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, et al. (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17:1158-1173.
36. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, et al. (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75.
37. Moriki N, Ito M, Seko T, Kureishi Y, Okamoto R, Nakakuki T, Kongo M, Isaka N, Kaibuchi K, and Nakano T (2004) RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 27:263-270.
38. Netherton SJ and Maurice DH (2005) Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67:263-272.
39. Nobes CD and Hall A (1999) Rho GTPases control polarity, protrusion and adhesion during cell movement. J Cell Biol 144:1235-1244.
40. Pelletier S, Julien C, Popoff MR, Lamarche-Vane N, and Meloche S (2005) Cyclic AMP induces morphological changes of vascular smooth muscle cells by inhibiting a rac-dependent signaling pathway. J Cell Physiol 204:412-422.
41. Phillips PG, Long L, Wilkins MR, and Morrell NW (2005) cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol 288:L103-L115.
42. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, Huston E, Sullivan M, and Houslay MD (2001) Molecular cloning, genomic positioning, promoter identification and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 59:996-1011.
43. Rybalkin SD, Rybalkina I, Beavo JA, and Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151-157.
44. Sette C and Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534.
45. Shepherd MC, Baillie GS, Stirling DI, and Houslay MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142:339-351.
46. Spina D (2004) The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 3:231-236.
47. Sullivan M, Rena G, Begg F, Gordon L, Olsen AS, and Houslay MD (1998) Identification and characterization of the human homologue of the short PDE4A cAMP specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochem J 333:693-703.
48. Tasken K and Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137-167.
49. Tilley D and Maurice DH (2005) Vascular smooth muscle cell phenotype-dependent phosphodiesterase D4 short form expression: role of differential histone acetylation on cAMP-regulated function. Mol Pharmacol 68:596-605.
50. Vadiveloo PK, Filonzi EL, Stanton HR, and Hamilton JA (1997) G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis 133:61-69.
51. Vicini E and Conti M (1997) Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 11:839-850.
52. Wallace DA, Johnston LA, Huston E, Macmaster D, Houslay TM, Cheung YF, Campbell L, Millen JE, Smith RA, Gall I, et al. (2005) Identification and Characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol Pharmacol 67:1920-1934.
53. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (Wash DC) 288:1822-1825.
54. Zagotta WN and Siegelbaum SA (1996) Structure and function of cyclic nucleotidegated channels. Annu Rev Neurosci 19:235-263.